

Route of administration	Experimental model	The effects	Ref.
Chronic (3 weeks), orally	Transgenic rats overexpressing both the human renin and angiotensinogen genes (dTGR)	<ul style="list-style-type: none"> <li>reduced mortality</li> <li>lowered blood pressure</li> <li>ameliorated cardiac hypertrophy, albuminuria, cell infiltration, and matrix deposition in the heart and kidney</li> </ul>	[110]
Chronic (10 weeks), orally	Streptozotocin-induced diabetic rats	<ul style="list-style-type: none"> <li>reduced renal aldosterone content and urinary albumin excretion</li> <li>reduced mRNA expression of NF<math>\kappa</math> B, TNF<math>\alpha</math>, IL-6 and TGF<math>\beta</math></li> </ul>	[113]
Chronic (2 weeks), ICV minipumps infusion	Wistar rats infused with Na <sup>+</sup> -rich artificial cerebrospinal fluid	<ul style="list-style-type: none"> <li>prevented the Na<sup>+</sup>-induced increase in hypothalamic aldosterone</li> <li>prevented most of the increases in resting BP and sympathoexcitatory and pressor responses to air stress and the baroreflex impairment</li> </ul>	[114]
Chronic (7 days and 12 weeks), orally	Model of post-myocardial infarction heart failure in rats	<ul style="list-style-type: none"> <li>improved left ventricular haemodynamics</li> <li>reduced LV hypertrophy and collagen accumulation to the same extent</li> <li>reduced the CHF-related enhancements in LV reactive oxygen species</li> <li>reduced-oxidized glutathione ratio and aortic nicotinamide adenine dinucleotide phosphate oxidase activity</li> <li>normalized the CHF-induced impairment of endothelium-dependent vasodilatation</li> <li>normalization of the CHF-induced reduction in AT<sub>2</sub> receptor protein levels</li> </ul>	[115]
Chronic (4 weeks), orally	Uninephrectomized Sprague–Dawley rats, on high salt diet with Ang II infusion	<ul style="list-style-type: none"> <li>reduced plasma aldosterone level</li> <li>prevention of the hypertensive response to uninephrectomy and high salt</li> <li>decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt</li> <li>prevented Ang-II and salt induced increase in renal and heart PAI-1 mRNA protein expression</li> </ul>	[116]
Chronic, (2 weeks), ICV or subcutaneously minipumps infusion	Dahl salt-sensitive rats on high salt diet	<ul style="list-style-type: none"> <li>prevented the increase in hypothalamic aldosterone and 30 mmHg of the 50-mmHg BP increase induced by high salt intake</li> </ul>	[117]
Chronic, (4 weeks), ICV minipumps infusion	Model of myocardial infarction in rats	<ul style="list-style-type: none"> <li>prevented post-MI increase of aldosterone in the hippocampus</li> <li>attenuated post-MI changes in left ventricular dimensions and ejection fraction</li> <li>improvement of haemodynamics parameters</li> <li>attenuated post-MI cardiac fibrosis and cardiomyocyte diameter</li> </ul>	[118]
Chronic (3-7 weeks), ICV or subcutaneously minipumps infusion	Dahl salt-sensitive rats on high salt diet	<ul style="list-style-type: none"> <li>lowered blood pressure</li> </ul>	[119]
Chronic (10 weeks), orally	Model of atherosclerosis, apolipoprotein E knockout mice on low salt diet	<ul style="list-style-type: none"> <li>reduced lesion area to values similar to normal diet</li> <li>changes in the expression of the inflammation markers (C-reactive protein, monocyte chemoattractant protein-1, interleukin-6, nuclear factor kappa B and intercellular adhesion molecule-1)</li> </ul>	[120]

	Chronic, (7 days) subcutaneously	Model of oxygen- induced retinopathy in rats	<ul style="list-style-type: none"> <li>• reduced neovascularization and neovascular tufts</li> <li>• normalized the increase in vascular endothelial growth factor mRNA</li> <li>• reduced OIR-induced increase in mRNA for tumor necrosis factor-<math>\alpha</math>, intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and monocyte chemoattractant molecule 1</li> </ul>	[121]
--	--	--	---	-------

**Table 3. Aldosterone synthase inhibitor (FAD286) in the experimental studies.**